Is Checkpoint Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NASDAQ: CKPT) stock is to Buy CKPT stock.
Out of 3 analysts, 1 (33.33%) are recommending CKPT as a Strong Buy, 0 (0%) are recommending CKPT as a Buy, 2 (66.67%) are recommending CKPT as a Hold, 0 (0%) are recommending CKPT as a Sell, and 0 (0%) are recommending CKPT as a Strong Sell.
What is CKPT's earnings growth forecast for 2025-2025?
(NASDAQ: CKPT) Checkpoint Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Checkpoint Therapeutics's earnings in 2025 is -$56,240,000.
In 2025, CKPT is forecast to generate $11,726,923 in earnings, with the lowest earnings forecast at $11,726,923 and the highest earnings forecast at $11,726,923.
What is CKPT's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: CKPT) forecast ROE is N/A, which is considered weak.
What is CKPT's Price Target?
According to 3 Wall Street analysts that have issued a 1 year CKPT price target, the average CKPT price target is $4.33, with the highest CKPT stock price forecast at $4.80 and the lowest CKPT stock price forecast at $4.10.
On average, Wall Street analysts predict that Checkpoint Therapeutics's share price could reach $4.33 by Mar 31, 2026. The average Checkpoint Therapeutics stock price prediction forecasts a potential upside of 7.25% from the current CKPT share price of $4.04.
What is CKPT's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: CKPT) Checkpoint Therapeutics's current Earnings Per Share (EPS) is -$1.42. In 2025, CKPT's EPS is forecast to hit $0.14 (min: $0.14, max: $0.14).
What is CKPT's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: CKPT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.52%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.